INSIGHTS ON DRUG DEVELOPMENT

• How Biocatalysts Address Process Development Issues

  Antje Gupta, General Manager of Cambrex IEP in Wiesbaden, on where biocatalysis outperforms conventional chemistry — matching enzyme classes to target conversions and production volumes to find the more scalable, more economical route.

• Discovery Core Rheometer: Easy To Use. Hard To Beat.

  Explore how advanced rheological testing delivers deeper insight into material behavior, from flow and yield stress to quality control decisions, using guided workflows that simplify setup.

• Development Of A High Sensitivity SPE-LC-MS/MS Assay

  Achieve ultra-sensitive glucagon quantification with ionKey/MS, μElution SPE, and advanced MS fragmentation to deliver low LOD, reduced sample loss, and enhanced confidence in results.

• Why Pharmaceutical Scientists Trust The Discovery Core Rheometer

  Drug formulations demand more than single‑point viscosity data. Explore how rheology reveals stability, flow, and structural behavior across suspensions, topicals, and injectables.

• Choosing The Best Amorphous Dispersion Path Before It Costs You

  6/22/2026

  Parallel screening across multiple solid dispersion platforms early optimizes drug solubility and stability, building a strong technical foundation that prevents costly development delays.

• Optimize Your RNA-LNP Delivery With Ionizable Lipids

  4/3/2025

  Ionizable lipids play a crucial role in optimizing LNP delivery. Discover how lipid nanoparticles revolutionize intracellular drug delivery to enhance RNA vaccines, cell therapies, protein replacement, and gene editing.

• mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models

  6/19/2026

  Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.

• Characterization Of Pharmaceutical Materials With Modulated DSC

  12/30/2024

  Modulated DSC addresses challenges in pharmaceutical material characterization, enabling precise analysis of glass transitions, and overlapping transitions, enhancing insights beyond standard DSC.

• Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development

  3/3/2026

  Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.